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Upregulation of Phosphodiesterase 
type 5 in the Hyperplastic Prostate
Wenhao Zhang1,*,†, Ning Zang2,†, Yaoming Jiang3,*, Ping Chen1, Xinghuan Wang1 & 
Xinhua Zhang1
Both erectile dysfunction (ED) and lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia 
(BPH) are common in the aging male. Numerous clinical trials have demonstrated the efficacy 
and safety of phosphodiesterase type 5 inhibitors (PDE5-Is) for treating LUTS/BPH with/without 
ED. However, the influence of BPH on prostatic PDE5 expression has never been studied. A 
testosterone-induced rat model of BPH was developed and human hyperplastic prostate specimens 
were harvested during cystoprostatectomy. PDE5, nNOS, eNOS and α1-adrenoreceptor subtypes 
(α1aARs, α1bARs and α1dARs) were determined with real-time RT-PCR for rat tissues whilst PDE5 
and α1-adrenoreceptor subtypes were determined in human samples. PDE5 was further analyzed 
with Western-blot and histological examination. Serum testosterone was measured with ELISA. 
The rat BPH model was validated as having a significantly enlarged prostate. PDE5 localized mainly 
in fibromuscular stroma in prostate. Our data showed a significant and previously undocumented 
upregulation of PDE5 in both rat and human BPH, along with increased expression of nNOS and 
α1dARs for rat tissues and α1aARs for human BPH. The upregulation of PDE5 in the hyperplastic 
prostate could explain the mechanism and contribute to the high effectiveness of PDE5-Is for 
treating LUTS/BPH. Fibromuscular stroma could be the main target for PDE5-Is within prostate.
Lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) are common in aging male. 
The prevalence of BPH is approximately 40% for men in their fifties and reaches to 90% for men in their 
eighties or above1 and the incidence of LUTS is around 25% for men in their 50 s or older2. This disor-
der is typically characterized by enlargement of the prostate gland, constriction of the urethra, and the 
emergence of LUTS. Besides prostatectomy, present pharmaceutical treatments for LUTS/BPH are aimed 
at relieving symptoms and slowing the progression of the disease. Current oral medical treatment options 
are 1) α -adrenoceptor antagonists (α -blockers, ABs) which reduce urethral resistance by attenuating the 
tension of smooth muscle (SM) fibers located in the prostate 2) 5α -reductase inhibitors (5ARIs) which 
are involved in the hormonal control of prostate growth 3) muscarinic receptor antagonists (MRAs) and 
4) a “new emerging treatment” phosphodiesterase type 5 inhibitors (PDE5-Is)3,4. Several clinical studies 
have demonstrated the efficacy and safety of PDE5-Is in treating LUTS/BPH. We recently performed a 
systematic review and network meta-analysis including 64 RCTs with 28196 participants comparing the 
effectiveness of different oral drug therapies for LUTS/BPH5. This data showed that among all the drug 
treatments, PDE5-Is combined with ABs ranked highest in efficacy for decreasing the international pros-
tate symptom score (IPSS) including total score, storage subscore and voiding subscore. PDE5-Is used 
alone also showed promising efficacy, with the exception of not improving maximum flow rate (Qmax). 
However, the mechanisms by which PDE5-Is alleviates LUTS/BPH remains unclear despite the perfor-
mance of several basic science studies. Recent experimental studies reported a functional role of PDE5 in 
lower urinary tracts and suggested a potential significance of the PDE5-nitric oxide (NO)/cyclic guano-
sine monophosphate (cGMP) cell-signaling pathway in the control of urogenital SM6–9. In the current 
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study we used a rat BPH model and human hyperplastic prostate tissue to investigate the expression of 
genes involved in the major pathways regulating SM tone, with PDE5 emphasized.
Results
BPH rat model. The testosterone (T)-supplementation rat model of BPH was validated through 
increased weight of the ventral prostate and seminal vesicle (Fig. 1 and Table 1, P < 0.001) by 1.6-fold 
and 2-fold, respectively. Accordingly, T level was found significantly increased for BPH animals (Table 1, 
P = 0.016). The body weight of BPH rats was significantly decreased (Table 1, P < 0.001), which may be 
ascribed to the physiological effect of T. No difference in bladder weight was found between the 2 groups 
(Table 1). The prostate index [prostate wet weight (mg)/ body weight (g)] was also calculated with a 1.8-
fold increase observed in the BPH group (Table 1, P < 0.001).
Histological examination. Differential histopathology was observed between human and rat BPH 
by H-E and Masson’s trichrome staining. Specifically, in the rat BPH model, the hyperplasia of the pros-
tate occurred mainly in the epithelium, whereas the stromal component decreased (mainly through the 
loss of collagen fibers, not SM) (Figs 2a,b and 3a). In contrast, in the human BPH sample, both stroma 
(mainly through increased SM) and epithelia increased significantly (even though there was a loss of 
collagen fibers) (Figs 2c,d and 3b).
Immunostaining. As shown in Fig. 4, immunohistology demonstrated PDE5 was present in the rat 
prostate, predominantly in fibromuscular stroma cells and endothelial and SM cells of blood vessels. The 
human prostate also demonstrated stromal immunolocalization of PDE5. Negative controls omitting the 
primary antibody failed to stain and positive control using rat and human lung tissue showed a strong 
immune positivity. Furthermore, the localization of nNOS in human prostate was also investigated, 
nNOS was partly colocalized with PDE5 in stromal matrix (Fig. 4).
The mRNA expression of PDE5 and related molecules. Expression of PDE5, nNOS, eNOS, 
α 1aARs, α 1bARs, α 1dARs mRNA were determined using quantitative real time RT-PCR in the rat model 
(Fig.  5). BPH upregulated PDE5 expression by approximately 2-fold at the gene level (P = 0.001). Real 
time RT-PCR also showed that nNOS (P = 0.003) and α 1dARs (P < 0.001) were augmented significantly 
in BPH group but with no change in the level of eNOS, α 1aARs and α 1bARs. The expression of PDE5, 
α 1aARs α 1bARs and α 1dARs mRNA were also determined in human prostate (Fig.  6). BPH equally 
Figure 1. Typical photograph from a BPH and control rat. (a) bladder, (b) ventral prostate, (c) seminal 
vesicle. 
Group
Body weight (g)
Ventral prostate 
weight (mg)
Seminal vesicles 
weight (mg)
Prostate 
index
T level 
(ng/mL)
Bladder 
weight (mg)Initial Final
Control 274.3(13.1) 429.8(32.7) 778.3(135.3) 1001.8(288.5) 1.8(0.3) 4.4(0.4) 151.2(17.9)
BPH 272.6(12.7) 387.2(13.7)** 1231.3(131.4)** 2483.9(360.6)** 3.2(0.3)** 6.2(0.5)* 147.4(17.3)
P value 0.706 0.000 0.000 0.000 0.000 0.016 0.560
Table 1. Variation of biometric and physiological parameters in control and BPH rats. P values 
calculated by unpaired t test. Data are mean ± SD. **P < 0.01 VS control, *P < 0.05 VS control.
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Figure 2. Histological examination of prostate. Masson’s trichrome staining of prostate tissue. Prostatic SM 
cells were stained red, collagen fibers were stained blue and epithelial cells were stained orange. (a) Normal 
rat prostate. (b) BPH rat prostate. Hyperplastic prostate occurred mainly at the epithelial compartment 
and typical features of glandular hypertrophy was observed including increased acinus number, papillary 
fronds protruded into the glandular cavities and the epithelial layer thickened. (magnification × 100). 
(c) Normal human prostate. (d) Human BPH prostate. An obvious stromal hyperplasia was observed. 
(magnification × 100, n = 8 for each group).
Figure 3. Histological quantification. Area percentage of different component between normal and BPH 
group. The percentage of each component were quantified from three random 100 × fields of each tissue 
slices (n = 8 from each group) (a) rat prostate. (b) human prostate. Boxes, mean; bars, ± S.E.M; **P < 0.01 vs. 
control; *P < 0.05 vs. control.
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Figure 4. Immunolocalization of PDE5 and nNOS. (a) Rat prostate. Left: PDE5 mainly distributed in 
fibromuscular stroma (black arrows) as well as in the endothelial and smooth muscle cells of blood vessels 
(black triangle). Middle: rat lung as positive control. Right: negative control. (magnification ×200).  
(b) Human prostate. Left: Cy3-immunofluorescence (red) indicates the PDE5 which was abundantly 
observed in the fibromuscular stroma. Middle: DAPI (blue) indicates nuclear staining. Right: Merged 
image. (magnification ×200). (c) Double immunofluorescence labeling of PDE5 and nNOS. Left: Cy3-
immunofluorescence (red) indicates PDE5. Middle: Cy2-immuno fluorescence (green) indicates nNOS. 
Right: Merge image indicates the partly colocalization of PDE5 and nNOS in fibromuscular stroma. 
(magnification ×200). (d) Negative control by omitting the primary antibody. (magnification ×200).  
(e) Human lung tissue was used as positive control for PDE5. (magnification ×200, n = 8 from each  
group).
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upregulated PDE5 and α 1aARs expression by 2.5-fold (P = 0.006, P = 0.02, respectively) with no change 
of α 1bARs and α 1dARs expression.
The translational expression of PDE5. Expression of PDE5 protein was quantified by Western 
blot analysis (Fig. 7). Two major protein bands were detected at a molecular weight of 85 and 95 kDa, as 
reported in our previous study10. A significant 1.8-fold and over 3-fold increase of PDE5 at translational 
level was found for BPH rat (P = 0.013) and human (P < 0.001), respectively.
Discussion
Our T induced BPH rat model was validated through hyperplasia of the prostate and seminal vesicle 
(androgen-sensitive organs) with both organ weights significantly increasing. We observed body weight 
loss with T supplementation, which may be due to increased daily activity and an increased ratio of 
lean body mass/fat body mass. In parallel with previous observations11,12, T injection mainly led to a 
notable involution of acinar epithelium hyperplasia, such as increased acinus amount, papillary fronds 
protruding into the glandular cavities and thickening of the epithelial layer while the stromal compart-
ment was relatively decreased. Masson’s trichrome staining further quantified that the BPH epithelia 
was significantly increased compared with control even though the SM content remained unchanged. 
In contrast, in the human condition, a predominant stromal hyperplasia was observed with an increase 
in SM of 2.2-fold.
In both rat and human prostate tissue, PDE5 gene and protein are highly expressed and was immu-
nodistributed exclusively in the stroma. Our finding is in agreement with Fibbi et al.6 that PDE5 was 
immunolocalized only in the fibromuscular stroma and vascular (endothelial and SM cells) in the rat 
and human prostate with no immunoreactivity in the glandular area. However, it contrasts with the 
findings by Ückert et al.8 that the glandular and subglandular areas of human prostate also expressed 
PDE5. This disparity in immunolocalization of PDE5 could be attributed to the different primary anti-
bodies employed as well as the different sources of tissue. In the study of Fibbi et al., prostate tissue 
was obtained from BPH patients while Ückert et al. study obtained tissue from prostate cancer patients. 
However, Wang et al. recently found PDE5 was expressed in both acinar epithelium as well as peri-
acinar SM and lobe-specific PDE5 expression patterns were observed in this study13. They speculated 
that such expression might be associated with glandular secretory function. The stroma-predominant 
distribution of PDE5 would explain the functional role of PDE5-Is in the control of prostatic SM. In 
organ bath studies, we and others showed that the exposure of isolated rat or human prostate tissues 
to PDE5-Is could produce a relaxation of precontracted prostatic strips10,14. Furthermore, our result of 
double-immunofluorescent labeling of PDE5 and nNOS from present study showed that these two pro-
teins partly colocalize to prostatic fibromuscular stroma, providing further support for a functional role 
of PDE5-Is in the NO/cGMP mediated relaxation of prostatic SM.
Importantly, our data for the first time demonstrates an increased expression of PDE5 gene and pro-
tein in both the rat and human hyperplastic prostate, with a more significant increase observed in human 
BPH than in that of rat. We did not perform image quantification for PDE5 immunohistology since the 
results of quantitative RT-PCR and Western blot are more convincing for quantification. Increased PDE5 
expression may be associated with elevated T level. Our findings in the prostate are broadly consistent 
with other lower urinary tract tissues (corpus cavernosum, bladder and vas deferens) that the expression 
of PDE5 is T regulated15–18. In our rat model, after 28 days T supplementation, a significant increase in 
serum T level was detected by ELISA. For human BPH, it is well known that its development is closely 
associated with androgens and anti-androgen therapy with 5ARIs are effective for larger prostate over 
40 ml, although increased estrogen/T ratio seems more important for BPH development19. In particular, 
dihydrotestosterone (DHT) was assumed to play a causative role in the etiology of BPH although this 
theory still remains speculative and controversial. Previous studies20–22 reported levels of intraprostatic 
DHT increased but these findings were not confirmed by later study23, probably due to different methods 
of tissue retrieval, methods of tissue processing and assays of androgen determination used24. In addition, 
the elevated PDE5 expression may be ascribed to the stromal hyperplasia and increased SM content. Lin 
et al. reported that PDE5 gene is not directly regulated by T and the decreased expression of PDE5 in 
castrated animals is due to reduced SM content25,26. Indeed, the stroma-predominant human BPH could 
contribute to greater PDE5 expression than that of epithelium-predominant rat BPH, as observed in our 
study. However, in our rat model, histological quantification showed that connective tissue decreased 
while SM content remained unchanged. Furthermore, in our previous studies on a castrated rat model10, 
the expression of PDE5 was decreased significantly despite a clear relative increase of the stromal layer 
observed. Therefore, the increased expression of PDE5 observed in our study is more likely to relate to 
increased gene and protein expression rather than to a change in morphology.
The upregulation of PDE5 in hyperplastic prostate could provide a rationale for the high efficacy of 
PDE5-Is for treating patients with LUTS/BPH with/without ED. It is well known that prostate enlarge-
ment is aging related2. In our study, the normal prostate was collected from young brain-dead men with 
the average age of 29 years old, while BPH specimens were harvested from the elderly with the mean age 
of 67 years old. Samples included in our study could represent clinical scenarios. We didn’t care the loca-
tion of tumor in bladder. Since the first clinical trial conducted by Sairam et al.27 in 2002 with sildenafil 
for treating LUTS/BPH/ED patients, many clinical trials have been performed demonstrating efficacy 
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and safety of PDE5-Is for treating LUTS/BPH. Our recent systematic review and network meta-analysis5 
showed that among all the drug treatments, PDE5-Is combined with ABs ranked highest in efficacy for 
relieving IPSS total score, storage subscore and voiding subscore. PDE5-Is alone also showed promis-
ing effect except on Qmax. Although a number of basic investigations have been done, the mechanisms 
involved in this treatment are still unclear. To date, a consensus has been reached that the potential 
mechanisms of PDE5-Is in treating LUTS/BPH are multifactorial28: (1) Slight-to-moderate relaxation of 
muscle tone in prostate and bladder; (2) Significant dilation of local blood vessels which provide adequate 
Figure 6. mRNA expression of PDE5 and α1-adrenoreceptor subtypes (α1aARs, α1bARs and α1dARs) 
in human prostate (n = 9, 3 replicates per experiment). Boxes, mean; bars, ± S.E.M; **P < 0.01 vs. control; 
*P < 0.05 vs. control.
Figure 5. mRNA expression of PDE5, nitric oxide synthase isoforms (nNOS and eNOS) and  
α1-adrenoreceptor subtypes (α1aARs, α1bARs and α1dARs) in rat ventral prostrate (n = 15, 3 replicates 
per experiment). Boxes, mean; bars, ± S.E.M; **P < 0.01 vs. control; *P < 0.05 vs. control.
www.nature.com/scientificreports/
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blood; (3) Significant augmentation of oxygen perfusion to local organs; (4) Inhibition of afferent nerve 
activity of bladder; (5) Bluntness of intraprostatic inflammation; (6) Antiproliferation in prostate.
Additionally, expression of other molecular components involved pathways associated with prostatic 
SM contraction and relaxation were determined in the rat prostate. It was found that several of these 
genes were differentially modulated by BPH. In rat model, nNOS and α 1dARs mRNA were significantly 
increased with no change for eNOS, α 1aARs and α 1bARs. Our investigation of α 1AR subtypes was con-
sistent with Kojima et al. study, although a different BPH rat model was used29. Also, Hampel et al. 
found that in the lower urinary tract, upregulation of α 1dARs correlated with severe bladder hypertro-
phy and bladder outlet obstruction (BOO)30. These results suggested that α 1dARs may play a crucial 
role in rat BPH and BOO. In human, α 1ARs is richly expressed in the prostate and excessive activity of 
α 1-adrenergic SM contraction appears to be a common feature of symptomatic BPH31. Moreover, pre-
vious quantification of α 1ARs mRNA expression within human prostate has revealed that α 1aARs pre-
dominates, followed by α 1dARs and α 1bARs32. This predominance of α 1aARs is reportedly more marked 
Figure 7. Representative Western blot analysis and relative densitometric quantification of PDE5 in rat 
and human prostate. (a) Representative Western-blot bands of rat prostate. (b) Representative Western-
blot bands of human prostate. Two major specific bands of the expected sizes (85 and 95 kDa, green) are 
evident in all lanes, red bands indicates the protein markers. (c) Densitometric evaluation of rat prostatic 
PDE5 expression. (d) Densitometric evaluation of human prostatic PDE5 expression. β -actin expression 
was analyzed as a loading control, results are expressed as ratio of PDE5 in respect to β -actin (n = 10 for 
rat group, n = 8 for human group, 3 replicates per experiment). Boxes, mean; bars, ± S.E.M; *P < 0.05 vs. 
control, **P < 0.01 vs. control.
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in the hyperplastic prostate. Immunohistochemisty showed that the immunoreactivity for α 1aARs was 
exclusively located in the stroma and we consistently found a 2.5-fold increase of α 1aARs expression33,34. 
The expression of α 1bARs and α 1dARs were also examined in human prostate and no significant differ-
ence was observed. This discrepancy of α 1-adrenoreceptor subtypes mRNA expression between human 
and rats BPH could be explained by differences in tissue morphometry. The differential expression and 
role of different NOS isoforms in the prostate and BPH is interesting and would need to be defined 
through further experimentation.
In current study, inflammation almost always accompanied BPH. It would be also interesting to fur-
ther examine the inflammatory factors in prostate and explore whether prostatitis could affect the expres-
sion of PDE5 and the efficiency of its inhibitors in BPH/prostatitis patients. In conclusion, our data is 
the first report demonstrating an increase of PDE5 gene and protein expression both in rat and human 
hyperplastic prostate. Furthermore, the upregulation of PDE5 in BPH would enhance the efficacy of 
PDE5-Is within prostate and could therefore explain the possible mechanism and provide rationale for 
the use of PDE5-Is in treating patients with LUTS/BPH. In addition, fibromuscular stroma cells as well 
as endothelial and SM cells of blood vessels could be the main target tissue of PDE5-Is in the prostate.
Materials and Methods
Animal protocol. A total of 30 specific-pathogen-free (SPF) grade male Wistar rats (12 weeks), 
weighing 250–300 g, were used. Rats were randomly divided into two groups and fed water and rat chow 
ad libitum. One group (n = 15) were treated with 0.1 ml sesame oil as controls and the other (n = 15) 
were subcutaneously injected with 2 mg/d testosterone propionate (Shanghai Tongyong Medical Co., Ltd, 
Shanghai, China) for 28 days. Rats were weighed and sacrificed under anesthesia using a euthanasia solu-
tion containing 10% [w/v] chloral hydrate on day 29. The blood was collected from the abdominal aorta. 
The whole ventral prostatic lobes, seminal vesicles and bladder were harvested and weighed. Prostatic 
strips of 1 × 1 × 0.5 cm were put into 10% [v/v] neutral buffered formalin for histological examination 
and another portion of strips were put into RNA Sample Protector (Takara Bio. Inc.,Otsu, Shiga, Japan) 
for PCR analysis with the rest of the tissue frozen in liquid nitrogen and saved at − 80 °C. All animal 
experimental procedures were performed strictly in accordance with the care and use of laboratory ani-
mals (National Research Council, Washington, DC) and the related ethical regulations of our university.
Human specimens. Nine human normal prostate samples are obtained from young brain-dead men 
(mean age, 29.1 ± 1.7 years) undergoing organ donation surgery. Nine human BPH samples are obtained 
from patients (mean age, 67.7 ± 2.1 years) undergoing cystoprostatectomy for infiltrating bladder cancer 
without prostate infiltration and LUTS/BPH. Immediately after removal, tissue specimens were shock 
frozen in liquid nitrogen and stored at − 80 °C for subsequent analysis. All tissue samples were obtained 
after the approval of the Hospital Committee for Investigation in Humans and after receiving written 
informed consent from all patients or their relatives involved. Human study was conducted in accordance 
with the principles of the Declaration of Helsinki.
Serum testosterone level. After blood was collected, serum was then isolated as the supernatant 
fraction following centrifugation at 3000 g for 10 min. The measurement of T concentrations was via 
enzyme-linked immunosorbent assay (ELISA) according to the BlueGene Biotech (Shanghai, China) 
protocol.
Total RNA extraction and real-time RT-PCR. Total RNA was isolated from the frozen tissues using 
TaKaRa MiniBEST Universal RNA Extraction Kit (Takara Bio. Inc., Otsu, Shiga, Japan) according to the 
manufacturer’s protocol. 100 ng of RNA was added in the one-step real-time RT-PCR reaction system 
(Takara Bio. Inc.,Otsu, Shiga, Japan). The whole system was amplified in a 96-well plate in a 25 μ l reac-
tion volume with all samples run in triplicate, using a CFX96 Touch Real-Time PCR Detection System 
(BioRad, USA). The experimental protocol utilized was first reverse transcription (42 °C 5 min, 95 °C 
10 s), followed by an amplification program repeated for 40 cycles (95 °C for 5 s, then 60 °C for 30 s), 
using SYBR Green measurement. For rat prostate tissue, the following targets were amplified: PDE5, 
neuronal NOS (nNOS), endothelial NOS (eNOS), and α 1-adrenoreceptor subtypes (α 1aARs, α 1bARs and 
α 1dARs), and for human tissue, PDE5, α 1aARs, α 1bARs and α 1dARs were investigated. Primer sequences 
are shown in Table 2. For relative quantification, gene expression was normalized to expression of β -actin 
housekeeping gene and compared by 2−ΔΔCT method.
SDS-PAGE and Western blot analysis. Proteins were extracted from frozen samples using the 
CelLytic™ NuCLEAR™ Extraction Kit (Sigma-Aldrich, Saint Louis, USA) and 100 μ g of each sample 
was eletrophoresed on a 10% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel (Wuhan Boster 
Biological Technology Ltd, Wuhan, China) and transferred to polyvinylidene fluoride (PVDF) membrane 
(Millipore, Billerica, MA, USA) using a Bio-Rad wet transfer system. The membrane was blocked for 
2 h at room temperature with Tris-buffered saline with 0.1% [v/v] Tween (TBST) containing 5% [w/v] 
non-fat dry milk solution. The membrane was incubated overnight with primary PDE5 antibody (Rabbit 
polyclonal to PDE5A, ab64179) at dilution of 1:1000 (Abcam, Cambridge, UK). Membranes were washed 
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with TBST three times and incubated at room temperature for 1 h with an IRDye 800CW conjugated 
goat anti-rabbit IgG (LI-COR, Lincoln, USA) at dilutions of 1:15000. After washing, the blots were vis-
ualized by scanning using Li-Cor Odyssey Imager (Li-Cor, Lincoln, USA). The bands were quantified 
by densitometry using Li-Cor Odyssey software. A polyclonal rabbit antibody against β -actin (1:2000; 
Abcam) was used as a control to ascertain equivalent loading.
H&E staining and Masson’s trichrome staining. Rat and human prostate tissues fixed in 10% 
[v/v] neutral buffered formalin for 24–36 h were processed routinely for paraffin embedding. The 
paraffin-embedded tissue sections (4 μ M) were stained with hematoxylin and eosin using stand-
ard techniques. The paraffin sections were deparaffinized in xylene followed by graded alcohols. 
Masson composite staining solution (Fuzhou Maxim Biotech Co., Ltd., Fuzhou, China) was added 
Target Gene Primer Sequence
Rat
PDE5A
 Forward 5′ -TTGGAGAGCCCTTGAACATCA-3′ 
 Reverse 5′ -GTAGCCTGTAATTTGGTCAACTTCTG-3′ 
nNOS
 Forward 5′ -GGCAAACATGACTTCCGAGTGT-3′ 
 Reverse 5′ -CCCCAAGGTAGAGCCATCTG-3′ 
eNOS
 Forward 5′ -CACCCACTGAGCAGTATTGG-3′ 
 Reverse 5′ -CCTGGGAACCACTCCTTTTG-3′ 
α 1aARs
 Forward 5′ -GCCCTTCTCTGCCATCTTG-3′ 
 Reverse 5′ -GGCCGCCCAGATATTGC-3′ 
α 1bARs
 Forward 5′ -CCAGGAGTTCCATAGCTGTCAAAC-3′ 
 Reverse 5′ -CCGACTACAATGCCCAAGGT-3′ 
α 1dARs
 Forward 5′ -TGCGCCACTCGCTCAA-3′ 
 Reverse 5′ -CCAAAGCAGAGCCAGAATGG-3′ 
β -actin
 Forward 5′ -ACCAACTGGGACGATATGGAGAAGA-3′ 
 Reverse 5′ -TACGACCAGAGGCATACAGGGACAA-3′ 
Human
PDE5A
 Forward 5′ -CCTCCATCACGAGAGTCATTTCAG-3′ 
 Reverse 5′ -CCACCTTGACCATCTCATGACTTTA-3′ 
α 1aARs
 Forward 5′ -CCACTTCAACGAAAACCACCA-3′ 
 Reverse 5′ -AAAATCCCCTCACTTCCATCAA-3′ 
α 1bARs
 Forward 5′ -CTCAACCCCATCATCTACCCA-3′ 
 Reverse 5′ -GCACCCGAGGATGCG-3′ 
α 1dARs
 Forward 5′ -ACCACGCGCAGCCTCGAGGCAGGC-3′ 
 Reverse 5′ -GAGCCGAGCTGCGGAAGGTGTGGCC-3′ 
β -actin
 Forward 5′ -TGACGTGGACATCCGCAAAG-3′ 
 Reverse 5′ -CTGGAAGGTGGACAGCGAGG-3′ 
Table 2. Primer sequences used to amplify target genes by real-time RT-PCR.
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dropwise for 10 min. The sections were subsequently washed with distilled water, differentiated in 
phosphomolybdic-phosphotungstic acid solution for 10 min, and incubated with blue staining solution 
for 5–10 min. Rinsed briefly in distilled water and differentiated in 1% acetic acid solution for 2 min-
utes. After dehydrated quickly through 95% alcohol, absolute alcohol, the sections were cemented using 
neutral gum for observation. Using this procedure, prostatic stroma SM cells were stained red, collagen 
fibers were stained blue and epithelial cells were stained orange. In each sample, we analyzed three areas 
under magnification (×100). The area percentage of SM, collagen fibers and glandular epithelium were 
quantitated with Image pro plus 5.0, respectively.
Immunohistochemistry. Sections for immunohistochemistry were deparaffinized in xylene followed 
by graded alcohols. Antigen retrieval was performed in 10 mM sodium citrate buffer (pH 6.0) and heated 
to 96 °C for 3 min. Endogenous peroxidase activity was blocked by using 3% [v/v] H2O2 solution in meth-
anol at room temperature for 10 min. Sections were incubated with 15% [v/v] normal goat serum for 1 h 
at 37 °C to block nonspecific binding. 100 μ l appropriately diluted PDE5A primary antibody (1:100) was 
applied to the sections on the slides and incubated in a humidified chamber at 4 °C overnight. Then the 
sections were stained by routine immunohistochemistry methods. Negative controls were performed for 
all samples by omitting the primary antibodies. Rat lung tissue was used as a positive control for PDE5A 
staining. All the stained sections were imaged using Olympus-DP72 light microscope (Olympus, Japan).
Immunofluroscence. Human prostate were embedded in Tissue-Tec OCT compound (SakuraFinetek 
Japan, Tokyo, Japan) and snap frozen. Then tissue was sectioned in 10 μ M thick slices and thaw, mounted 
onto glass slides using a cryostat (Leica CM 1850, Wetzlar, Germany), air-dried, and fixed for 10 min 
in ice-cold acetone. Slides were washed in PBS and then incubated for 2 h in a mixture of PBS sup-
plemented with 0.2% [v/v] Triton X-100 and 0.1% [w/v] bovine serum albumin, followed by incuba-
tion overnight with the primary antibody (rabbit polyclonal to PDE5A, 1:100) and antibody mixture 
of the PDE5A antibody (1:100) and goat polyclonal to nNOS (1:50, Abcam, ab1376 Cambridge, UK). 
The secondary antibodies employed to visualize the localization of the two primary antibodies (Jackson 
ImmunoResearch Inc. West Grove, PA, USA) were Cy3-conjugated goat anti-rabbit IgG (1:1000) and 
Cy2-conjugated donkey anti-goat IgG (1:400). DAPI was used for staining the nucleus. Negative controls 
were performed for all samples by omitting the primary antibodies. Human lung tissue was used as a 
positive control for PDE5A staining. Visualization was done with a laser microscope (Olympus, Tokyo, 
Japan). Colocalization analysis was performed using NIS-Elements Viewer 3.20 (Nikon, Japan).
All experimental protocol were approved by the research committee of Wuhan University.
Statistical analysis. Results are expressed as the mean ± SD in table and mean ± SEM in bar graph. 
Student’s t test was used to analyze the differences between two groups. Statistical analyses were per-
formed using GraphPad Prism v5.0 (La Jolla, CA). A P < 0.05 was considered statistically significant.
Ethical standards. All procedures performed in studies involving human participants were in accord-
ance with the ethical standards of the research committee of Wuhan University and the principles of the 
Declaration of Helsinki. All participants gave written informed consent before taking part in the study.
All procedures performed in studies involving animals were in accordance with the care and use of 
laboratory animals (National Research Council, Washington, DC) and the ethical standards of Wuhan 
University.
All experimental protocol were approved by the research committee of Wuhan University.
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